Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Of 4 Major Drug Wholesalers, Only Medipal to Increase Operating Profits in FY2011: Mizuho
July 25, 2011
- FDA Accepts Application for Dacogen for AML: Eisai
July 25, 2011
- Lyrica Shows Efficacy for Fibromyalgia in PIII in Japan: Pfizer
July 25, 2011
- NBI Expects Surge in Sales of Prazaxa after Lifting of Ban on Long-term Prescription
July 25, 2011
- Shionogi Licenses IPF Treatment Pirfenidone to Ildong of South Korea
July 25, 2011
- EPPV Finds No Safety-related Problems with Rasuritek: sanofi-aventis
July 25, 2011
- Lantus Plus One Mealtime Dose of Apidra Non-inferior to Insulin Aspart: Sanofi
July 25, 2011
- Eisai Obtains Marketing Rights to 2 Drugs from Orion in China
July 25, 2011
- Aricept Generics Approved from 33 Companies
July 25, 2011
- Novo Nordisk's Ultra-Long-Acting Insulin Reduces Incidence of Hypoglycemia
July 25, 2011
- Astellas to Market Pfizer's Caduet from October
July 25, 2011
- DSP to Launch Aricept Generics to Expand Product Lineup in CNS Field
July 25, 2011
- 4,000 Patients Registered with All-Case Survey on Orencia: Bristol-Myers
July 25, 2011
- Astellas Files Suit Against Sandoz Canada Over Generic Version of Prograf
July 25, 2011
- Nippon Chemiphar to Launch Generic Version of Aricept in Nov.
July 25, 2011
- Chugai to Take Safety Measures for Tarceva in Patients with Pancreatic Cancer
July 25, 2011
- Chugai to Fully Recommence Production at Utsunomiya Plant in August
July 25, 2011
- Nichi-Iko to Copromote Radicut Generic with sanofi-aventis
July 25, 2011
- Therapy Using Human Stem Cells to Be Covered by Health Insurance for First Time
July 25, 2011
- Drug Production in March Down as Much as 65% in 3 Quake-hit Prefectures: Korosho
July 25, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…